Abstract
Medpace will report second-quarter 2026 results on July 22, 2026 Post-Mkt; this preview compiles the latest quarterly actuals and the company’s projections alongside recent institutional commentary to frame expectations for revenue, margins, and adjusted EPS.
Market Forecast
Consensus for the current quarter points to revenue of 688.74 million US dollars with year-over-year growth of 27.83%, EBIT of 140.31 million with 27.69% growth, and EPS of 3.97 with 34.07% growth. The company’s prior report and disclosures imply healthy operating leverage; adjusted EPS is projected to rise faster than revenue, while EBIT expansion signals stable-to-improving conversion of sales to profit; year-over-year figures support this acceleration.
Management’s indicated mix remains anchored by core service categories with balanced demand across therapeutic areas; new awards and backlog conversion are viewed as the key drivers, while hiring and pricing remain supportive. The largest growth potential sits in the metabolic program portfolio at 237.56 million US dollars last quarter; its size and award cadence make it a principal lever for incremental revenue despite normal quarter-to-quarter variability.
Last Quarter Review
Medpace delivered revenue of 706.60 million US dollars, a gross profit margin of 71.94%, net profit attributable to shareholders of 124.00 million US dollars, a net profit margin of 17.53%, and adjusted EPS of 4.28, reflecting year-over-year growth of 26.50% for revenue and 16.62% for EPS. A key highlight was EBIT of 141.50 million, exceeding internal and external estimates, which underscored consistent operating discipline alongside robust backlog conversion.
Main business highlights: the metabolic portfolio contributed 237.56 million US dollars, oncology 201.24 million, central nervous system 80.21 million, cardiology 56.26 million, anti-viral and anti-infective 38.02 million, and other services 93.32 million; therapeutic breadth continued to diversify revenue and underpin award momentum.
Current Quarter Outlook
Core clinical development services
Revenue is projected at 688.74 million US dollars, up 27.83% year over year, with EBIT estimated at 140.31 million and EPS at 3.97. The implied trajectory suggests solid conversion of funded backlog and ongoing strength in mid-to-late stage program execution. Pricing discipline and utilization should help protect gross margin, while labor and pass-through dynamics could introduce normal seasonality. The quarter’s stock reaction is likely to hinge on net new awards commentary and any updates to full-year bookings-to-billings trends, which investors use as a read-through for sustainability into the next twelve months.
Metabolic programs
The metabolic category, at 237.56 million US dollars last quarter, remains the single largest revenue contributor, positioning it as the most impactful near-term growth vector. Investor attention is centered on award flow in cardiometabolic and obesity-related studies, where timelines and patient recruitment velocity can meaningfully swing quarterly revenue recognition. If management highlights stronger-than-expected backlog conversion in these programs, it could support upside to revenue and EPS versus the current estimates; conversely, recruitment pacing or site start delays could defer recognition into later quarters without changing full-year demand.
Margin drivers and stock-price sensitivities
The last quarter’s 71.94% gross margin and 17.53% net margin establish a high-quality baseline; maintaining these levels would affirm that wage inflation and site costs are being offset by scale efficiencies and pricing. The EPS estimate growth of 34.07% outpacing revenue suggests a favorable mix and operating leverage; investors will parse any color on project-level margin, pass-through rates, and SG&A growth versus headcount expansion. Share performance this quarter is most sensitive to: commentary on net new awards and backlog health, visibility on start-up timelines for larger studies, and any update to full-year margin guardrails relative to hiring and facility investments.
Analyst Opinions
Across recent institutional previews and rating updates, the prevailing stance trends bullish, with positive views outweighing cautious ones. A majority of analysts highlight sustained double-digit bookings, strong conversion from backlog to revenue, and resilient margins as the underpinnings of above-consensus EPS quality. Representative commentary emphasizes that Medpace’s estimate trajectory for revenue growth near the high-20% range, coupled with faster EPS expansion, reflects disciplined cost control and a robust award environment in metabolic and oncology categories. On the cautious side, minority views point to potential timing risk in project starts and typical CRO seasonality, but these are generally framed as pacing issues rather than demand deterioration. The majority outlook expects in-line to modestly better results versus consensus, with the market reaction contingent on the tone of forward bookings and any full-year guidance refinements.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments